The Biobank Integrating Longitudinal ERCP Within a Prospective Chronic Pancreatitis Cohort
Key facts
- Who runs it
- First People's Hospital of Hangzhou
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 1,500 people, planned
- Started
- 15 Aug 2026
- Expected to end
- 31 Aug 2031
- Type of study
- Observational
- Treatments tested
- This observational cohort study does not involve any interventions
- Record updated
- 18 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥ 18 years, with no sex restrictions
- Meets the diagnostic criteria for chronic pancreatitis, with a definitive diagnosis of chronic pancreatitis based on imaging, pathology, or pancreatic function tests
- Receiving medical care at the study center and willing to accept long-term follow-up management
- Able to cooperate with baseline data collection and scheduled follow-ups
- Provided written informed consent
Who cannot take part
- Concomitant malignancies
- Concurrent severe systemic diseases with an expected life expectancy of < 1 year
- History of major pancreatic resection or pancreaticoduodenectomy
- History of major gastrointestinal surgery
- Severe psychiatric disorders, cognitive dysfunction, or assessed by the investigator as having extremely poor compliance, rendering the participant unable to complete the scheduled follow-up plan
- Other relevant conditions deemed by the investigator as potentially affecting the study results or compromising participant safety
- Pregnant or lactating population
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The Biobank Integrating Longitudinal ERCP within a Prospective Chronic Pancreatitis Cohort (BILE-CP) is a prospective longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The study plans to consecutively enroll 1,500 patients with chronic pancreatitis for long-term follow-up (scheduled every 6 months). This cohort encompasses patients across the entire disease course of chronic pancreatitis, with a particular focus on and in-depth tracking of a sub-cohort of patients undergoing ERCP treatments. During baseline and follow-up visits, researchers will collect multidimensional data from participants, including sociodemographics, diet and lifestyle, emotional status and sleep quality, clinical phenotypes and disease characteristics, ERCP intervention details, clinical laboratory and imaging examinations, continuous glucose monitoring (CGM), and traditional Chinese medicine indicators. Concurrently, multi-site biological samples will be collected, including but not limited to blood, feces, bile, saliva, tongue coating, and urine.
The group in the trial
- BILE-CP Cohort: Patients with Chronic Pancreatitis Meeting Inclusion and Exclusion Criteria
All eligible patients clinically diagnosed with chronic pancreatitis and receiving standard clinical treatment at the research center. This observational cohort study excludes interventions. And the primary clinical exposure factors of interest include ERCP, lifestyle, and the use of traditional Chinese medicine and herbal remedies.
Treatment: This observational cohort study does not involve any interventions
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 18 August 2026